S-phase cells in diseased human liver determined by an in vitro BrdU-anti-BrdU method.
Using a monoclonal antibody to bromodeoxyuridine, we studied the cell kinetics of human hepatocellular carcinoma, liver cirrhosis, chronic active hepatitis and alcoholic liver fibrosis. Specimens were taken either by biopsy or surgery and immediately incubated with 0.1% bromodeoxyuridine solution at 37 degrees C for 45 min. After in vitro labeling, the bromodeoxyuridine taken up by the nuclei of S-phase cells was determined by the avidin-biotin-peroxidase complex method, using an anti-bromodeoxyuridine monoclonal antibody as the first antibody. The number of positive nuclei in 1,000 hepatic cells was counted, and the bromodeoxyuridine labeling index was expressed per thousand. The mean bromodeoxyuridine labeling index +/- S.D. of the cancerous portion of hepatocellular carcinoma, the noncancerous portion of hepatocellular carcinoma, liver cirrhosis, chronic active hepatitis and alcoholic liver fibrosis were 64.1 +/- 31.3, 33.6 +/- 14.4, 23.2 +/- 20.8, 9.1 +/- 6.1 and 21.6 +/- 13.0, respectively. The mean bromodeoxyuridine labeling index of the hepatocellular carcinoma cancerous portion was statistically higher than that of any other group. There was no statistical difference by the t test or the Wilcoxon test between the noncancerous portion of hepatocellular carcinoma and liver cirrhosis, and these two groups were proved interdependent by chi 2 test (Fisher's exact test), whether they were subdivided by bromodeoxyuridine labeling index greater than or equal to 10 or not. Bromodeoxyuridine labeling index was not significantly correlated with the usual biochemical parameters such as serum AST, ALT, gamma-GTP, alkaline phosphatase, lactate dehydrogenase, cholinesterase, albumin, and alpha-fetoprotein.(ABSTRACT TRUNCATED AT 250 WORDS)
Shimizu
A
A
Kanagawa Cancer Center, Clinical Research Institute and Hospital, Japan.
Tarao
K
K
Takemiya
S
S
Harada
M
M
Inoue
T
T
Ono
T
T
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D001973:Bromodeoxyuridine / Q000493:pharmacokinetics*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D002453:Cell Cycle; D004247:DNA / Q000096:biosynthesis; D005260:Female; D006521:Hepatitis, Chronic / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007399:Interphase; D008103:Liver Cirrhosis / Q000378:metabolism; D008104:Liver Cirrhosis, Alcoholic / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D013936:Thymidine / Q000378:metabolism
D000911:Antibodies, Monoclonal; D004247:DNA; D001973:Bromodeoxyuridine; D013936:Thymidine